In a communication on April 14, 2025, Bristol Myers Squibb said mavacamten did not meet its dual primary endpoints of changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score ...

37% of patients taking mavacamten had achieved the study's main goal compared to 17% of the placebo group. Patients were deemed to have met the treatment target if they had a 1.5 point or greater ...

Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten ... s second-largest pharma market – is a key growth area for Camzyos, with some estimates ...